Open Access
Subscription Access
An Objectives, Indications, Mechanism of Action, Pharmacokinetics, Administration, Adverse Effects, Drug-Drug Interactions, Contra Indication, Toxicity and Health Care Team Outcomes of Enalapril Drug
Abstract
One well-known angiotensin-converting enzyme inhibitor that has been approved by the US Food and Drug Administration (FDA) for the treatment of asymptomatic left ventricular dysfunction, persistent hypertension, and heart failure is enalapril maleate. A fixed-dose combination of hydrochlorothiazide and enalapril has been approved by the FDA. Because it reduces mortality and slows the progression to symptomatic heart failure, enalapril is used to treat asymptomatic left ventricular dysfunction.
This activity provides information on enalapril's indications, mechanism of action, adverse event profile, dosage considerations, monitoring techniques, and possible drug interactions. It highlights the medication's crucial role as an effective treatment for hypertension and related conditions. This exercise also emphasizes the value of an interprofessional healthcare team working together to effectively use and manage enalapril, guaranteeing shared decision-making and patient safety while providing patients with hypertension and associated conditions with the best care possible.
References
Alsheikh Ali, A. A., Wang, P. J., Rand, W., Konstam, M. A., Homoud, M. K., Link, M. S., Estes, N. A., Salem, D. N., & Al Ahmad, A. M. (2004). Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. American Heart Journal, 147(6), 1061–1065. https://doi.org/10.1016/j.ahj.2003.12.033 jmcp.org+4ahajournals.org+4journals.sagepub.com+4acpjournals.org+4pubmed.ncbi.nlm.nih.gov+4onlinejcf.com+4
Shah, A., Gandhi, D., Srivastava, S., Shah, K. J., & Mansukhani, R. (2017). Heart failure: A class review of pharmacotherapy. P & T: A Peer Reviewed Journal for Formulary Management, 42(7), 464–472. (PMC free article) researchgate.net+9researchwithrutgers.com+9nursing.ceconnection.com+9
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., Milano, C. A., Nnacheta, L. C., Sandhu, A. T., Stevenson, L. W., Vardeny, O., Vest, A. R., & Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Williamson, J. D., … Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13–e115. https://doi.org/10.1161/HYP.0000000000000065
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., Wainford, R. D., Williams, B., & Schutte, A. E. (2020). 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension, 75(6), 1334–1357. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026
Reed, B. N., & Sueta, C. A. (2015). Stage B: what is the evidence for treatment of asymptomatic left ventricular dysfunction? Current Cardiology Reviews, 11(1), 18–22.
Marre, M., Chatellier, G., Leblanc, H., Guyenne, T. T., Ménard, J., & Passa, P. (1988). Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ, 297(6656), 1092–1095. https://doi.org/10.1136/bmj.297.6656.1092
de Boer, I. H., Khunti, K., Sadušky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., … Bakris, G. (2022). Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care, 45(12), 3075–3090.
Todd, P. A., & Goa, K. L. (1992). Enalapril: A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs, 43(3), 346–381. https://doi.org/10.2165/00003495-199243030-00006
Yoshiyama, M., Nakamura, Y., Omura, T., Izumi, Y., Matsumoto, R., Oda, S., Takeuchi, K., Kim, S., Iwao, H., & Yoshikawa, J. (2005). Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice. Heart, 91(8), 1080–1085. https://doi.org/10.1136/hrt.2004.054900
Düsing, R. (2016). Pharmacological interventions into the renin–angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: Effects beyond blood pressure lowering. Therapeutic Advances in Cardiovascular Disease, 10(3), 151–161.
Portolés, A., Terleira, A., Almeida, S., García–Arenillas, M., Caturla, M. C., Filipe, A., & Vargas, E. (2004). Bioequivalence study of two formulations of enalapril at a single oral dose of 20 mg: A randomized, two way, open label, crossover study in healthy volunteers. Current Therapeutic Research – Clinical and Experimental, 65(1), 34–46.
Ho, J. K., Moriarty, F., Manly, J. J., Larson, E. B., Evans, D. A., Rajan, K. B., … Hassan, L. (2021). Blood–brain barrier crossing renin–angiotensin drugs and cognition in the elderly: A meta analysis. Hypertension, 78(3), 629–643. https://doi.org/10.1161/HYPERTENSIONAHA.121.17701
Stage, C., Jürgens, G., Guski, L. S., Thomsen, R., Bjerre, D., Ferrero–Miliani, L., … INDICES Consortium. (2017). The pharmacokinetics of enalapril in relation to CES1 genotype in healthy Danish volunteers. Basic & Clinical Pharmacology & Toxicology, 121(6), 487–492.
Thomsen, R., Rasmussen, H. B., Linnet, K., & INDICES Consortium. (2014). In vitro drug metabolism by human carboxylesterase 1: Focus on angiotensin converting enzyme inhibitors. Drug Metabolism and Disposition, 42(1), 126–133. https://doi.org/10.1124/dmd.113.055316
Smeets, N. J. L., Litjens, C. H. C., van den Heuvel, J. J. M. W., van Hove, H., van den Broek, P., Russel, F. G. M., Koenderink, J. B., & de Wildt, S. N. (2020). Completing the enalaprilat excretion pathway: Renal handling by the proximal tubule. Pharmaceutics, 12(10), 10.3390/pharmaceutics12100934
American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. (2019). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. Obstetrics & Gynecology, 133(1), e26–e50. https://doi.org/10.1097/AOG.0000000000003026
Buawangpong, N., Teekachunhatean, S., & Koonrungsesomboon, N. (2020). Adverse pregnancy outcomes associated with first trimester exposure to angiotensin converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta analysis. Pharmacology Research & Perspectives, 8(5), e00644. https://doi.org/10.1002/prp2.644
National Institute of Child Health and Human Development. (2024, June 15). Drugs and Lactation Database (LactMed®): Enalapril. [Internet database].
Flynn, J. T., Kaelber, D. C., Baker Smith, C. M., Blowey, D., Carroll, A. E., Daniels, S. R., … Subcommittee on Screening and Management of High Blood Pressure in Children. (2017). Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics, 140(3), e20171904. https://doi.org/10.1542/peds.2017-1904
Juárez Cedillo, T., Martinez Hernández, C., Hernández Constantino, A., García Cruz, J. C., Avalos Mejía, A. M., Sánchez Hurtado, L. A., Islas Pérez, V., & Hansten, P. D. (2016). Clinical weighting of drug–drug interactions in hospitalized elderly. Basic & Clinical Pharmacology & Toxicology, 118(4), 298–305. https://doi.org/10.1111/bcpt.12511
Ben Salem, C., Badreddine, A., Fathallah, N., Slim, R., & Hmouda, H. (2014). Drug induced hyperkalemia. Drug Safety, 37(9), 677–692. https://doi.org/10.1007/s40264-014-0202-0
Pinto, B., Jadhav, U., Singhai, P., Sadhanandham, S., & Shah, N. (2020). ACEI induced cough: A review of current evidence and its practical implications for optimal cardiovascular risk reduction. Indian Heart Journal, 72(5), 345–350. https://doi.org/10.1016/j.ihj.2020.09.015
Simon, L. V., Hashmi, M. F., & Farrell, M. W. (2023). Hyperkalemia. In StatPearls. StatPearls Publishing.
Gibbs, C. R., Lip, G. Y., & Beevers, D. G. (1999). Angioedema due to ACE inhibitors: Increased risk in patients of African origin. British Journal of Clinical Pharmacology, 48(6), 861–865. https://doi.org/10.1046/j.1365-2125.1999.00027.x
Brown, N. J., Ray, W. A., Snowden, M., & Griffin, M. R. (1996). Black Americans have an increased rate of angiotensin converting enzyme inhibitor–associated angioedema. Clinical Pharmacology & Therapeutics, 60(1), 8–13. https://doi.org/10.1016/S0009-9236(96)90030-4
Kostis, J. B., Kim, H. J., Rusnak, J., Casale, T., Kaplan, A., Corren, J., & Levy, E. (2005). Incidence and characteristics of angioedema associated with enalapril. Archives of Internal Medicine, 165(14), 1637–1642. https://doi.org/10.1001/archinte.165.14.1637
Schmidt, T. D., & McGrath, K. M. (2002). Angiotensin converting enzyme inhibitor angioedema of the intestine: A case report and review of the literature. The American Journal of the Medical Sciences, 324(2), 106–108. https://doi.org/10.1097/00000441-200208000-00007
Oudit, G., Girgrah, N., & Allard, J. (2001). ACE inhibitor induced angioedema of the intestine: Case report, incidence, pathophysiology, diagnosis and management. Canadian Journal of Gastroenterology, 15(12), 827–832. https://doi.org/10.1155/2001/827...
Duerr, M., Glander, P., Diekmann, F., Dragun, D., Neumayer, H. H., & Budde, K. (2010). Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clinical Journal of the American Society of Nephrology, 5(4), 703–708. https://doi.org/10.2215/CJN.06190809
Charmillon, A., Deibener, J., Kaminsky, P., & Louis, G. (2014). Angioedema induced by angiotensin converting enzyme inhibitors, potentiated by m TOR inhibitors: Successful treatment with icatibant. Intensive Care Medicine, 40(6), 893–894. https://doi.org/10.1007/s00134-014-3334-1
Todd, P., Levison, D., & Farthing, M. J. (1990). Enalapril related cholestatic jaundice. Journal of the Royal Society of Medicine, 83(4), 271–272. https://doi.org/10.1177/014107689008300415
Gil Braga, B., Cravo, M., Neves, P., Pinto, F., & Mendonça, C. (2022). A rare case of unilateral tongue edema with angiotensin converting enzyme inhibitors. Acta Médica Portuguesa, 35(7–8), 588–590. https://doi.org/10.20344/amp.17524
Kao, C. D., Chang, J. B., Chen, J. T., Wu, Z. A., Shan, D. E., & Liao, K. K. (2004). Hypotension due to interaction between lisinopril and tizanidine. Annals of Pharmacotherapy, 38(11), 1840–1843. https://doi.org/10.1345/aph.1E595
Johnson, T. R., & Tobias, J. D. (2000). Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension. The Journal of Child Neurology, 15(12), 818–819. https://doi.org/10.1177/088307380001501207.
Refbacks
- There are currently no refbacks.